What is Amycretin?

A single molecule that activates both GLP-1 and amylin receptors, tested by injection and as a tablet in early obesity trials.

Amycretin in the library · Metabolic & Weight Peptides · Human Trials · What are peptides?

23 registered trials · 4 indexed papers · 2 human / 0 animal studies

From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.

What it is

Amycretin is described as Novo Nordisk's first-in-class unimolecular GLP-1 and amylin receptor agonist: one peptide instead of the two-drug CagriSema approach.

Mechanism (as described)

  • It combines GLP-1 receptor activity (appetite, insulin) with amylin receptor activity (satiety, slower gastric emptying) in one molecule (Kuhre et al., 2025).

Status

Investigational (phase 2/3).

Registered human trials (23)

TrialPhaseStatusYearEnrolled
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose WeightPhase 3not yet recruiting20261000
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose WeightPhase 3recruiting20261150
A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce PainPhase 3recruiting2026400
AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight LossPhase 3active not recruiting2026606
A Research Study Looking at How NNC0487-0111 Affects Food Intake, Appetite and Metabolism After Meals in People With ObesityPhase 1recruiting2026120
AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce PainPhase 3recruiting2026400
AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose WeightPhase 3recruiting2026630
Investigating How NNC0487-0111 Regulates Insulin of Adults With Type 2 DiabetesPhase 1recruiting202680
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and ObesityPhase 3recruiting20265610
AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep ApnoeaPhase 3recruiting2026300
AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep ApnoeaPhase 3recruiting2026300
A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in People With Reduced Liver Function and Normal Liver FunctionPhase 1not yet recruiting202635
A Research Study to See How NNC0487-0111 Affects the Body's Energy Use After a Weight Loss in Adults Living With Overweight or Obesity, Compared to a Low-calorie Diet or PlaceboPhase 1recruiting2026120
AMAZE 10: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People in Japan With Excess Body Weight Lose WeightPhase 3recruiting2026400
A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants After 10 Days of Oral DosingPhase 1completed202529
A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants When Injected Under the Skin.Phase 1completed202536
A Research Study Looking at How the Compound NNC0487-0111 Works With Birth Control Pills and Affects Emptying of the Stomach in Women Not Able to Become PregnantPhase 1completed202443
A Research Study Looking at Different Oral Formulations and the Effect of Food Intake on How the Medicine NNC0487-0111 Behaves in the Body of Participants Living With Overweight or ObesityPhase 1completed2024133
A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 DiabetesPhase 2completed2024448
A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney FunctionPhase 1completed202442
A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With ObesityPhase 1completed202336
A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the SkinPhase 2completed2023125
A Research Study on How NNC0487-0111 Works in People With Overweight or ObesityPhase 1completed2022144

Peer-reviewed studies (4)

PaperAuthorsJournalYearType
Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trialMora P et al.Lancet (London, England)2026Randomized Controlled Trial
Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trialMora P et al.Lancet (London, England)2026Randomized Controlled Trial
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled studyDahl K et al.Lancet (London, England)2025Randomized Controlled Trial
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trialGasiorek A et al.Lancet (London, England)2025Randomized Controlled Trial

More cited research

Conditions researched

Related compounds

FAQ

How many registered human trials study Amycretin?

The PeptideWhiz trial index lists 23 registered trials for Amycretin, the most recent from 2026.

How much published research exists on Amycretin?

The PeptideWhiz paper index links 4 PubMed papers to Amycretin; by study type, 2 human and 0 animal studies.

Which conditions is Amycretin researched for?

Fat loss, obesity & body recomposition, Heart repair: after heart attack, heart failure & enlarged heart, Insulin resistance, prediabetes & type 2 diabetes, Osteoarthritis, cartilage loss & avoiding joint replacement, Sleep apnea (obstructive), Sleep problems (incl. insomnia on peptides).

Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).

Reported dosing ranges from research